Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: Current perspective on reduced-dosage regimens

Archives of Medical Science

Volumn 8, Issue 3, 2012, Pages 542-548

  Jackowska, Teresa ^a   Pluta, Justyna ^b  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b Pfizer Poland   (Poland)

Author keywords

13 valent; 7 valent; Pneumococcal; Schedule; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; CHILD; CLINICAL DECISION MAKING; DRUG COST; DRUG DOSE REGIMEN; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE;

EID: 84864067346     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.29410     Document Type: Review

References (44)

1. CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46: 1-24.
2. CDC. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000; 49: 1-38.
3. CDC. Invasive pneumococcal disease in young children before licensure of 13- valent pneumococcal conjugate vaccine - United States, 2007. MMWR 2010; 59: 253-7.
4. Robinson K, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285: 1729-35. (Pubitemid 32259907)
5. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
6. CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP). MMWR 2010; 59: 258-61.
7. Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J 2010; 29: 756-62.
8. Patrzałek M, Albrecht P, Sobczyński M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 2010; 29: 787-92.
9. Immunisation against infectious disease - 'The Green Book', 2007. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-079917 (accessed 5 June 2011).
10. Centers for disease control and prevention. Notice to readers: limited supply of pneumococcal conjugate vaccine: suspension of recommendation for fourth dose. MMWR 2004; 53; 108-9.
11. Freed GL, Davis MM, Clark SJ. Variation in public and private supply of pneumococcal conjugate vaccine during a shartage. J Am Med Assoc 2003; 289: 575-8. (Pubitemid 37428629)
12. Centers for disease control and prevention. Limited supply of pneumococcal conjugate vaccine. MMWR 2003; 52: 1234.
13. Centers of disease control and prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000; 49(RR9).
14. World health organisation. WHO Technical Report Series, number 927. World health organization, Geneva, Switzerland, 2005.
15. Feavers I, Knezevic I, Powell M, Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 2009; 27: 3681-8.
16. Rennels MB, Edwards KM, Keyserling HI, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101: 604-11. (Pubitemid 28180141)
17. Ekström N, Ahman H, Verho J, et al. Finnish Otitis Media Strudy Group. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun 2005; 73: 369-77. (Pubitemid 40041129)
18. Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 2005; 23: 1703-8. (Pubitemid 40215704)
19. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46. (Pubitemid 36514704)
20. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9. (Pubitemid 32128672)
21. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permananet Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-95. (Pubitemid 30167436)
22. Käyhty H, Ahman H, Eriksson K, et al. Pneumococcal conjugate vaccine (PNCCRM) is immunogenic when administered at 3, 5 and 12 months of age. In: Proceedings of the 21st annual meeting of the European Society for Paediatric Infectious Diseases, 2003.
23. Käyhty H, Ahman H, Eriksson K, et al. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 2005; 24: 108-14. (Pubitemid 40250767)
24. Russell FM, Balloch A, Tang MLK, et al. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine 2009; 27: 5685-91.
25. Russell FM, Licciardi PV, Balloch A, et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 2010; 28: 3086-94.
26. Russell FM, Carapetis JR, Burton RL. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 2010; 29: 535-44.
27. Rodenburg GD, van Gils EJM, Veenhoven RH, et al. Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses. Vaccine 2010; 28: 1391-6.
28. Goldblatt G, Southern J, Ashton L, et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr Infect Dis J 2010; 29: 1-5.
29. De Wals P, Robin E, Fortin E, et al. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2008; 27: 963-8.
30. Deceuninck G, De Wals P, Boulianne N, et al. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J 2009; 29: 546-9.
31. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case control study. Lancet 2006; 368: 1495-502. (Pubitemid 44634693)
32. Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010; 28: 26427.
33. Ansaldi F, Sticchi L, Durando P, et al. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. J Int Med Res 2008; 36: 1255-60.
34. Durando P, Crovari P, Ansaldi, F, et al. Universal childhood immunization against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009; 27: 3459-62.
35. Crisinel PA, Chevalier I, Rallu F, et al. Invasive pneumococcal disease after implementation of a reduced threedose pneumococcal conjugate vaccine program: a pediatric tertiary care center experience. Eur J Pediatr 2010; 169: 1311-5.
36. Dinleyici EC, Kurogol Z. 6th world congress of the World Society for Pediatric Infectious Diseases (WSPID). Expert Rev Vaccines 2010; 9: 261-72.
37. Spijkerman J, van Gils EJ, Veenhoven RH. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis 2011; 17: 584-91.
38. Kaye P, Malkani R, Martin S, et al. Invasive pneumococcal disease (IPD) in England & Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines. http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/ 1245581527892 (accessed 1 July 2010).
39. Surveillence de maladies infectieuses pédiatriques en Belgique, 2007. http://www.iph.fgov.be/epidemio/epifr/plabfr/eradi07fr.pdf (accessed 1 July 2010).
40. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008; 26: 3277-81.
41. De carvalho Gomes H, Muscat M, Monnet DL, et al. Use of 7-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill 2009; 14: 1-6.
42. Vestrheim DF, Høiby EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010; 28: 2214-21.
43. Paradiso PR. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 2011; 52: 1241-7.
44. Prevenar 13: EPAR - product information, 2010. http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/001104/human-med-001220. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 (accessed 31 June 2010).